Dren Bio said it closed an oversubscribed $350 million private financing round to push dibotatug (DR-01) toward commercialization. The company plans to use proceeds for continued late-stage development, regulatory submissions, and a planned commercial launch, while also expanding the program into additional oncology and autoimmune indications. The lead asset is a CD94-targeting monoclonal antibody designed to selectively deplete pathogenic cytotoxic T cells while preserving broader immune function. Dren’s most advanced studies are in cytotoxic T-cell lymphoma and large granular lymphocytic leukemia (LGLL), both described as having limited current treatment options. The round was co-led by Juvia Group and Lightspeed Venture Partners and included participation from new and existing investors, with the syndicate featuring names such as Mirae Asset Capital Life Science, General Catalyst, OrbiMed, and Juvia-backed participation, alongside prior backers including 8VC and SR One. Dren’s platform claims include Targeted Myeloid Engager and Phagocytosis capabilities. For biotech investors, the deal highlights continued appetite for clinical-stage, mechanism-led antibody programs aimed at hard-to-treat rare hematologic cancers—while raising the bar for development and regulatory execution ahead of commercialization.